{
    "Trade/Device Name(s)": [
        "FreeStyle Libre 2 Flash Glucose Monitoring System",
        "FreeStyle Libre 3 Continuous Glucose Monitoring System"
    ],
    "Submitter Information": "Abbott Diabetes Care, Inc.",
    "510(k) Number": "K223435",
    "Predicate Device Reference 510(k) Number(s)": [
        "K222447"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "QBJ",
        "NBW"
    ],
    "Summary Letter Date": "April 13, 2023",
    "Summary Letter Received Date": "March 14, 2023",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 862.1355",
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Integrated Continuous Glucose Monitoring System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Interstitial fluid"
    ],
    "Specimen Container(s)": [
        "FreeStyle Libre 2 Sensor",
        "FreeStyle Libre 3 Sensor"
    ],
    "Instrument(s)/Platform(s)": [
        "FreeStyle Libre 2 Reader",
        "FreeStyle Libre 2 App (iOS and Android)",
        "FreeStyle Libre 3 Reader",
        "FreeStyle Libre 3 App (iOS and Android)"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric glucose measurement",
        "Glucose oxidase chemical reaction",
        "Factory calibrated continuous monitoring"
    ],
    "Methodologies": [
        "Continuous glucose monitoring"
    ],
    "Submission Type(s)": [
        "System",
        "Sensor",
        "Reader",
        "App"
    ],
    "Document Summary": "FDA 510(k) summary for FreeStyle Libre 2 and Libre 3 integrated continuous glucose monitoring systems for diabetes management.",
    "Indications for Use Summary": "Intended for real time continuous glucose monitoring with alarms for diabetes management in persons age 2 and older; replaces blood glucose testing for treatment decisions and aids in detecting episodes of hyper- and hypoglycemia; communicates with digitally connected devices including automated insulin dosing systems.",
    "fda_folder": "Clinical Chemistry"
}